@article{70e63ae485164eaab5ae59b1f2650a87,
title = "A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma",
author = "Lee, {Hans C.} and Shah, {Jatin J.} and Lei Feng and Manasanch, {Elisabet E.} and Rebecca Lu and Ashley Morphey and Brandon Crumpton and Patel, {Krina K.} and Wang, {Michael L.} and Raymond Alexanian and Thomas, {Sheeba K.} and Weber, {Donna M.} and Orlowski, {Robert Z.}",
note = "Funding Information: This work was supported in part by The MD Anderson Cancer Center Support Grant (P30 CA016672). H.C.L. would like to acknowledge support from the Baer Family Fund and the Goff-Street Foundation. Study funding was provided by Array BioPharma and Onyx Pharmaceuticals (Amgen, Inc.), who also provided filanesib and carfilzomib, respectively.",
year = "2019",
month = oct,
day = "1",
doi = "10.1038/s41408-019-0240-6",
language = "English (US)",
volume = "9",
journal = "Blood cancer journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "10",
}